Children's Oncology Group's 2013 blueprint for research: Neuroblastoma.
Park, Julie R. MD 1,*; Bagatell, Rochelle MD 2; London, Wendy B. MD 3; Maris, John M. MD 2; Cohn, Susan L. MD 4; Mattay, Katherine M. MD 5; Hogarty, Michael MD 2; on behalf of the COG Neuroblastoma Committee
[Review] Pediatric Blood & Cancer. 60(6):985-993, June 2013.

(Format: HTML, PDF)

Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors. Pediatr Blood Cancer 2013; 60: 985-993. (C) 2013 Wiley Periodicals, Inc.

Copyright (C) 2013 John Wiley & Sons, Inc.